PMID- 35662722
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Second-Generation Long-Acting Injectable Antipsychotics and the Risk of Treatment 
      Failure in a Population-Based Cohort.
PG  - 879224
LID - 10.3389/fphar.2022.879224 [doi]
LID - 879224
AB  - Introduction: Second-generation long-acting injectable antipsychotics (SG-LAIAs) 
      may improve outcomes compared to other antipsychotics. Real-world studies using 
      linked administrative databases play an important role in assessing the 
      comparative effectiveness of antipsychotic medications. Methods: We used a 
      prevalent new-user design in a population-based cohort of antipsychotic users 
      with diagnosis of a psychotic disorder to compare the primary outcome of 
      treatment failure, defined as psychiatric hospitalization, completed suicide, 
      incarceration, or treatment discontinuation. Additional outcomes were all-cause 
      mortality. SG-LAIA users were matched on a 1:1 basis with other antipsychotic 
      users based on the time-conditional propensity score, calendar time, and prior 
      antipsychotic exposure. Results: The use of LAIAs was not associated with a lower 
      risk of treatment failure than other antipsychotics (adjusted hazard ratio 1.07 
      and 95% confidence interval 0.98-1.15) but did reduce all-cause mortality 
      (adjusted hazard ratio 0.69 and 95% confidence interval 0.48-0.99). Monotherapy 
      with LAIAs was superior to other antipsychotic monotherapy (adjusted hazard ratio 
      for treatment failure 0.83 and 95% confidence interval 0.78-0.89), and LAIAs were 
      superior to other antipsychotics in antipsychotic-naive users (adjusted hazard 
      ratio for treatment failure 0.57 and 95% confidence interval 0.47-0.70). 
      Conclusion: In this population-based cohort, SG-LAIAs reduced the risk of 
      treatment failure in incident new users but not in prevalent new users.
CI  - Copyright (c) 2022 Janzen, Bolton, Leong, Kuo and Alessi-Severini.
FAU - Janzen, Donica
AU  - Janzen D
AD  - College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, 
      Winnipeg, MB, Canada.
FAU - Bolton, James M
AU  - Bolton JM
AD  - Department of Psychiatry, Max Rady College of Medicine, Rady Faculty of Health 
      Sciences, University of Manitoba, Winnipeg, MB, Canada.
FAU - Leong, Christine
AU  - Leong C
AD  - College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, 
      Winnipeg, MB, Canada.
AD  - Department of Psychiatry, Max Rady College of Medicine, Rady Faculty of Health 
      Sciences, University of Manitoba, Winnipeg, MB, Canada.
FAU - Kuo, I Fan
AU  - Kuo IF
AD  - College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, 
      Winnipeg, MB, Canada.
AD  - Pharmaceutical, Laboratory and Blood Services Division, Ministry of Health, New 
      Westminster, BC, Canada.
FAU - Alessi-Severini, Silvia
AU  - Alessi-Severini S
AD  - College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, 
      Winnipeg, MB, Canada.
LA  - eng
PT  - Journal Article
DEP - 20220519
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9160742
OTO - NOTNLM
OT  - antipsychotic treatment
OT  - comparative effectiveness
OT  - long-acting injectable and oral antipsychotics
OT  - psychotic disorders
OT  - real-world data
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/06/07 06:00
MHDA- 2022/06/07 06:01
PMCR- 2022/05/19
CRDT- 2022/06/06 13:47
PHST- 2022/02/19 00:00 [received]
PHST- 2022/04/11 00:00 [accepted]
PHST- 2022/06/06 13:47 [entrez]
PHST- 2022/06/07 06:00 [pubmed]
PHST- 2022/06/07 06:01 [medline]
PHST- 2022/05/19 00:00 [pmc-release]
AID - 879224 [pii]
AID - 10.3389/fphar.2022.879224 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 May 19;13:879224. doi: 10.3389/fphar.2022.879224. 
      eCollection 2022.